Sign In
Buy GILD
$131.40
+1.57 (+1.21%)
At Close: Jul 13, 2026
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.
09:23am, Sunday, 12'th Jul 2026
Gilead is seeing success with new oncology and inflammation therapies. The drugmaker went on an acquisition spree this past spring.
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
07:01pm, Friday, 10'th Jul 2026
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $129.83, denoting a -3.72% move from the preceding trading day.
2 Recession-Resistant Dividend Stocks to Buy and Hold
12:00pm, Friday, 10'th Jul 2026
You don't need to predict a recession to prepare your portfolio. These two stocks can help.
A Look at Gilead Sciences Inc (GILD) After 5.2% Gain -- GF Value $96.06 vs Price $136.36
05:17pm, Tuesday, 07'th Jul 2026
On July 07, 2026, Gilead Sciences Inc (GILD) shares rose 5.2% today, with the current price at $136.36. Over the past year, the stock has seen a 25.2% increase.
Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”
12:30pm, Tuesday, 07'th Jul 2026
On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as
Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?
03:41pm, Monday, 06'th Jul 2026
Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology growth strategy.
Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says
02:05pm, Monday, 06'th Jul 2026
HSBC upgraded Gilead Sciences Inc. (NASDAQ:GILD) on Monday, citing that the consensus is ‘too pessimistic' in its assumptions of continued decline once dolutegravir faces generics.
Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. Wi
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Thursday, 02'nd Jul 2026
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?
09:26am, Monday, 29'th Jun 2026
Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know
07:00pm, Thursday, 25'th Jun 2026
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05% move from the preceding trading day.
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use
11:21am, Thursday, 25'th Jun 2026
GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
04:29pm, Wednesday, 24'th Jun 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy), a firs
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC
12:25pm, Wednesday, 24'th Jun 2026
Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.
Gilead Sciences: The Market Is Underestimating Its Growth Runway
09:00am, Tuesday, 23'rd Jun 2026
Gilead Sciences offers a compelling long-term value opportunity after a significant pullback, with a "Buy" rating reaffirmed. GILD's core HIV franchise drives 72% of sales, with robust growth from Bik
